In 1956, the Pfizer subsidiary was opened in Vienna Austria. In the following decades, the merger of Pfizer with the pharmaceutical companies Mack (1988), SmithKline Beecham Animal Health, Warner Lambert. (2000) and Pharmacia (2003) the position of Pfizer Austria in the Austrian pharmaceutical market changed dramatically In May 2010, the merger with Wyeth, Pfizer so Austria is now also in the fields of biologics and vaccines of the leading pharmaceutical companies in Austria. The high growth rates require a steady increase in the number of employees. 1998 Pfizer Austria therefore moved to a larger house in the Silk Street in the 7th District of Vienna, with the beginning of 2005 in the 21st Floridotower District.
Pfizer is prioritizing its research and development efforts in areas with the greatest scientific and commercial promise: immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain, and vaccines. Through major research efforts across multiple modalities — including small molecules, biologics and vaccines — Pfizer is developing the medical solutions that will matter most to the people we serve. Specialized efforts in biosimilars as well as orphan and genetic diseases also illustrate our dedication to develop and deliver innovative medicines and vaccines that will benefit patients around the world.
Contact:
Address: Pfizer Corporation Austria Gesellschaft m.b.H, Floridsdorfer Hauptstraße 1, Postfach 439, 1210 Wien
Tel: 00 43 1 521 15 0
Fax: 00 43 1 52 69 13 2
E-Mail: pfizer.austriapfizer.com
Prof. Dr. Robin Rumler, country manager of Pfizer Austria, discusses the evolution of their operations, especially since taking over the TBE and meningitis vaccine production plant, as well as the…
Dr. Rumler, what is your assessment of the subsidiary’s current strengths and weaknesses, after three and half years of tenure? Pfizer currently ranks second in the overall pharmaceutical market in…
Ard van der Meij, country president of Novartis Group Austria, the nation’s leading pharmaceutical company, discusses the advantages in Austria for innovative companies and the steps required to bolster the…
Prof. Dr. Robin Rumler, country manager of Pfizer Austria, discusses the evolution of their operations, especially since taking over the TBE and meningitis vaccine production plant, as well as the…
Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research giants, Germany and Switzerland. Now, however, this perception is changing…
Dr. Sabine Mӧritz-Kaisergruber and Helmut Kaisergruber, CEOs of Astro Pharma, a young vibrant Austrian pharmaceutical company, discuss their tailored strategy to establish themselves within the Austrian market as well as…
Clemens Schödl, general manager of Gilead Austria, discusses Gilead’s footprint and reputation in Austria as the leading global player in HIV treatment and what must be done to bring Austrian…
Siegfried Leitner, general manager of Accord Austria and Germany, and CEO and co-founder of A-med, provides an insight into the early years of his Accord affiliate and how it was…
Robert Sauermann, head of the department of pharmaceutical affairs in the Main Association of Austrian Social Security Institutions, which publishes the national code of reimbursement, provides an in-depth look into…
Dr. Jan Oliver Huber, secretary general of the Association of the Pharmaceutical Industry in Austria, or PHARMIG, which represents 120 member companies and 95 percent of the medicinal product market…
Martin Peithner, CEO of Dr. Peithner and Austroplant, two leading medical companies focusing on homeopathic and herbal medicines in Austria, discusses the evolution of the companies over the last five…
Arnoldas Doviltis, general manager of Ferring Austria, a research-driven Swiss biopharmaceutical company, elaborates on the autonomous nature of local Ferring affiliates and how this allows a tailored approach to conduct…
Eva Bano, CEO of BANO, an exciting west Austrian company, discusses the company’s modern revamp and expansion from natural therapies to pharmaceutical products. She also explains the importance of a…
Erich Lehner, head of the life science branch at EY Austria, a worldwide leading consultancy firm, provides an insight into the current mandate of EY Austria as well as the…
See our Cookie Privacy Policy Here
